For instance, the CXCR4 antagonist BL-8040 has shown encouraging activity when combined with pembrolizumab and chemotherapy in pancreatic cancer [43], while balixafortide demonstrated synergistic efficacy with eribulin in metastatic breast cancer [44]. This evidence concerns the gene CXCR4 and familial pancreatic carcinoma.